Medical News

Illinois: Northwestern Professor Enlists Cervical Mucus in HIV Fight

September 22, 2011

The Collaboration for AIDS Vaccine Discovery, an effort backed by the Bill & Melinda Gates Foundation, has awarded $5.5 million to support a project at Northwestern University's Feinberg School of Medicine.

Thomas Hope, a professor of cellular and molecular biology at the school, is studying how a vaccine could use the body's mucus as a defense against HIV. He was among the first scientists to see how HIV functions, using a technique that attaches a fluorescent molecule to the virus, and then observing it under a microscope. Hope began studying how HIV enters body tissues.

"We are seeing the virus in the context of tissue, how the virus interacts with the surfaces of the female reproductive tract," Hope said. "We saw [virus] particles stuck above tissues but not entering them. They were getting caught in mucus. We got the idea that antibodies in mucus might be doing something." Hope's research will seek to develop this antibody as a vaccine.

Globally, most HIV transmissions are the result of heterosexual contact. "If you can protect women, then that would sort of stop that cycle and slow down the virus and have a big impact," Hope said.

Back to other news for September 2011

Adapted from:
Chicago Tribune
09.21.2011; Kelly April

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
See Also
What Did You Expect While You Were Expecting?
HIV/AIDS Resource Center for Women

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.